Could a common eye vitamin help fight cancer? early trial begins

NCT ID NCT05232409

Recruiting now Disease control Sponsor: Valley Health System Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This early-phase study is testing whether a dietary supplement called zeaxanthin, taken alone or with the immunotherapy drug pembrolizumab, is safe for people with advanced solid tumors that have not responded to standard treatments. The trial will enroll 72 participants to find the highest safe dose and check for side effects. It does not aim to cure cancer at this stage, but to gather safety data for future studies.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: zeaxanthin (a dietary supplement) alone or combined with pembrolizumab (an immunotherapy drug)
What this could lead to: If successful, this could point toward a new treatment option for advanced cancers that have not responded to standard therapies.
What could go wrong: This is a very early Phase 1 trial focused on safety and dosing, not effectiveness. It is small (72 people) and may not lead to a proven treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CANCER METASTATIC are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

metastatic malignant neoplasm Neoplasm Metastasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CANCER METASTATIC METASTATIC SOLID TUMOR

Contacts and locations

Locations

The Valley Hospital-Luckow Pavilion
RECRUITING

Paramus, New Jersey, 07652, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.